Literature DB >> 21549367

Antimüllerian hormone and polycystic ovary syndrome.

Yi-Hui Lin1, Wan-Chun Chiu, Chien-Hua Wu, Chii-Ruey Tzeng, Chun-Sen Hsu, Ming-I Hsu.   

Abstract

OBJECTIVE: To assess the relationship between antimüllerian hormone (AMH) and parameters related to polycystic ovary syndrome (PCOS).
DESIGN: Prospective study.
SETTING: Academic tertiary care center. PATIENT(S): A total of 290 women. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Parameters related to insulin resistance and metabolic syndrome. RESULT(S): Women with polycystic ovary morphology had significantly higher AMH levels than women in the control group. The prevalence of PCOS increased from 21% in the low-AMH (<4 ng/mL) group to 37% in the moderate-AMH (4-11 ng/mL) group and 80% in the high-AMH (>11 ng/mL) group. However, significant differences in insulin resistance parameters were not observed among groups. The results of the correlation analysis revealed that AMH levels were positively correlated with LH, total T, A, and total cholesterol content; however, AMH levels were negatively correlated with age, body mass index, and the number of menstrual cycles per year. AMH levels were not correlated with insulin resistance parameters. CONCLUSION(S): Elevated serum AMH levels increase the risk of PCOS but do not affect the risk of insulin resistance or metabolic syndrome.
Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21549367     DOI: 10.1016/j.fertnstert.2011.04.003

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  24 in total

1.  Anti-Müllerian hormone: a potential new tool in epidemiologic studies of female fecundability.

Authors:  Donna D Baird; Anne Z Steiner
Journal:  Am J Epidemiol       Date:  2012-01-12       Impact factor: 4.897

Review 2.  Anti-Müllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?

Authors:  Akira Iwase; Tomoko Nakamura; Satoko Osuka; Sachiko Takikawa; Maki Goto; Fumitaka Kikkawa
Journal:  Reprod Med Biol       Date:  2015-11-23

Review 3.  Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine.

Authors:  Vitaly A Kushnir; David B Seifer; David H Barad; Aritro Sen; Norbert Gleicher
Journal:  J Assist Reprod Genet       Date:  2017-06-22       Impact factor: 3.412

4.  Lack of Serum anti-Mullerian hormone responses after recombinant human chorionic gonadotropin stimulation in women with polycystic ovary syndrome.

Authors:  Heidi Cook-Andersen; Sandy S Chuan; Kevin Maas; Marcus A Rosencrantz; H Irene Su; Mark Lawson; Helen D Mason; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

5.  Role of AMH as Diagnostic Tool for Polycystic Ovarian Syndrome.

Authors:  Upma Saxena; Manisha Ramani; Pushpa Singh
Journal:  J Obstet Gynaecol India       Date:  2017-11-15

6.  Improvement of anti-Müllerian hormone and oxidative stress through regular exercise in Chinese women with polycystic ovary syndrome.

Authors:  Xia Wu; Heng Wu; Wenjiang Sun; Chen Wang
Journal:  Hormones (Athens)       Date:  2020-07-28       Impact factor: 2.885

7.  Follicle stimulating hormone and anti-Müllerian hormone per oocyte in predicting in vitro fertilization pregnancy in high responders: a cohort study.

Authors:  Andrea Weghofer; Ann Kim; David H Barad; Norbert Gleicher
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

8.  High Serum Anti-Müllerian Hormone Concentrations Are Associated With Poor Pregnancy Outcome in Fresh IVF/ICSI Cycle but Not Cumulative Live Birth Rate in PCOS Patients.

Authors:  Yaxin Guo; Shuai Liu; Shiqiao Hu; Fei Li; Lei Jin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-26       Impact factor: 5.555

9.  Longitudinal anti-müllerian hormone in women with polycystic ovary syndrome: an acupuncture randomized clinical trial.

Authors:  Jason Franasiak; Steven L Young; Christopher D Williams; Lisa M Pastore
Journal:  Evid Based Complement Alternat Med       Date:  2012-08-26       Impact factor: 2.629

10.  Anti-müllerian hormone is not associated with cardiometabolic risk factors in adolescent females.

Authors:  Emma L Anderson; Abigail Fraser; William McNally; Naveed Sattar; Hany Lashen; Richard Fleming; Scott M Nelson; Debbie A Lawlor
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.